Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Hyejin Ham (GIST Department of Chemistry) for technical assistance with the cellular experiments
Methods 11, 4760
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
Options include: Other GLP-1 receptor agonists with different side effects Different diabetes meds, like SGLT2 inhibitors Non-medical weight loss methods, like diet advice and lifestyle changes Its vital for patients to work with their doctor to find the best treatment
US$ 24.23
US$ 28.19
US$ 26.50
US$ 23.78
